Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Biohaven Ltd. ( (BHVN) ).
Biohaven Ltd. announced an update on its New Drug Application for troriluzole, intended for treating Spinocerebellar Ataxia in adults. The FDA extended the review period by three months in May 2025 to evaluate recent submissions, but later decided not to hold an advisory committee meeting, with a decision still expected in the fourth quarter of 2025.
The most recent analyst rating on (BHVN) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Biohaven Ltd. stock, see the BHVN Stock Forecast page.
Spark’s Take on BHVN Stock
According to Spark, TipRanks’ AI Analyst, BHVN is a Underperform.
Biohaven Ltd.’s overall stock score is low due to substantial financial challenges, including zero revenue and negative cash flow. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. However, the recent $600 million investment provides a positive outlook by supporting clinical developments. Despite this, the overall risks remain significant, making the stock a cautious investment.
To see Spark’s full report on BHVN stock, click here.
More about Biohaven Ltd.
Biohaven Ltd. operates in the pharmaceutical industry, focusing on the development of innovative drugs for neurological disorders. The company is engaged in creating treatments for conditions such as Spinocerebellar Ataxia.
Average Trading Volume: 1,972,645
Technical Sentiment Signal: Sell
Current Market Cap: $1.61B
For detailed information about BHVN stock, go to TipRanks’ Stock Analysis page.